Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about LIVER: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | LIVER |
Knowledge base pages for this entity
graph TD
LIVER["LIVER"]
LIVER -->|"modulates"| Mitochondrial_Dysfunction["Mitochondrial Dysfunction"]
LR_LOXL3["LR.LOXL3"] -->|"expressed in"| LIVER
Extracellular_Vesicles["Extracellular Vesicles"] -->|"modulates"| LIVER
Tumour_Extracellular_Vesicles["Tumour Extracellular Vesicles"] -->|"targets"| LIVER
LOXL3["LOXL3"] -->|"expressed in"| LIVER
Hypothalamus["Hypothalamus"] -->|"interacts"| LIVER
MIR_375["MIR-375"] -->|"expressed in"| LIVER
Mir_375["Mir-375"] -->|"expressed in"| LIVER
CLOCK["CLOCK"] -->|"expressed in"| LIVER| Target | Relation | Type | Str |
|---|---|---|---|
| ALZHEIMER'S DISEASE | involved_in | disease | 0.95 |
| Mitochondrial Dysfunction | modulates | process | 0.75 |
| Source | Relation | Type | Str |
|---|---|---|---|
| LR.LOXL3 | expressed_in | gene | 0.93 |
| LOXL3 | expressed_in | gene | 0.90 |
| Extracellular Vesicles | targets | process | 0.90 |
| APOE | expressed_in | gene | 0.90 |
| Extracellular Vesicles | modulates | process | 0.90 |
| Tumour Extracellular Vesicles | targets | process | 0.90 |
| MIR375 | expressed_in | gene | 0.90 |
| APOE | expressed_in | protein | 0.90 |
| Hypothalamus | interacts_with | cell_type | 0.85 |
| Mir-375 | expressed_in | biomarker | 0.80 |
| MIR-375 | expressed_in | gene | 0.80 |
| ST6GAL1 | expressed_in | gene | 0.80 |
| CLOCK | expressed_in | entity | 0.75 |
| BMAL1 | expressed_in | entity | 0.75 |
| ILC | expressed_in | cell_type | 0.72 |
| eVLPs | expressed_in | drug | 0.70 |
| AAV capsid variants | protects_against | drug | 0.70 |
| NAM | expressed_in | cell_type | 0.64 |
| PCSK9 | expressed_in | protein | 0.64 |
| LDLR | expressed_in | protein | 0.64 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Epigenetic clocks association with brain aging patterns in older women | exploratory | cognitive impairment and demen | 0.900 | 0.00 | human patients | proposed | N/A |
| Autophagy receptor identification for stress granule elimination | exploratory | neurodegenerative diseases | 0.900 | 0.00 | cultured cells under arsenite | proposed | N/A |
| Rab27a knockdown effects on microglia activation in developing brain | validation | 0.800 | 0.00 | Neonatal mice with dorsal subv | proposed | N/A | |
| Proposed experiment from debate on Mitochondrial transfer between astr | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| AAV-LRRK2 IND-Enabling Study Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Gap Junction Dysfunction Validation in Parkinson's Disease | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| AAV-LRRK2 Gene Therapy IND-Enabling Study Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| s:** - Test MCU overexpression specifically in layer II neurons in hea | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $200,000 |
| Proposed experiment from debate on Mitochondrial transfer between astr | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Axonal Transport Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson' | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Selective Neuronal Vulnerability to Aging — Mapping Why Specific Neuro | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Synaptic Mitochondrial Resilience Enhancement for Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Tumour extracellular vesicles and particles induce liver metabolic dysfunction. [PMID:37225988] | Wang G, Li J, Bojmar L, Chen H, Li Z, To | Nature | 2023 | 1 |
| Extracellular vesicles in fatty liver promote a metastatic tumor microenvironmen [PMID:37172577] | Wang Z, Kim SY, Tu W, Kim J, Xu A, Yang | Cell Metab | 2023 | 1 |
| KIF5A de novo mutation associated with myoclonic seizures and neonatal onset pro [PMID:27414745] | Rydzanicz M, Jagła M, Kosinska J, Tomasi | Clin Genet | 2017 | 1 |
| TRAK/Milton motor-adaptor proteins steer mitochondrial trafficking to axons and [PMID:23395375] | van Spronsen M, Mikhaylova M, Lipka J, S | Neuron | 2013 | 1 |
| Delineation of the TRAK binding regions of the kinesin-1 motor proteins. [PMID:24161670] | Randall TS, Moores C, Stephenson FA | FEBS Lett | 2013 | 1 |
| Rab27a and Rab27b control different steps of the exosome secretion pathway. [PMID:19966785] | Ostrowski M, Carmo NB, Krumeich S, Fange | Nat Cell Biol | 2010 | 1 |
| Case Report: Late-onset primary hemophagocytic lymphohistiocytosis leading to th [PMID:40852732] | ["Rausch J", "Herold S", "Liebh\u00e4use | Frontiers in immunology | 2025 | 0 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
| Therapeutic developments in pancreatic cancer. [PMID:37798442] | ["Hu Z", "O'Reilly E"] | Nature reviews. Gastroenterolo | 2024 | 0 |
| Tipifarnib Reduces Extracellular Vesicles and Protects From Heart Failure. [PMID:38847080] | Mallaredy V, Roy R, Cheng Z, Thej C, Ben | Circulation research | 2024 | 0 |
| P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting [PMID:38513667] | Zhang D, Zhang W, Ming C, Gao X, Yuan H, | Neuron | 2024 | 0 |
| Interruption of p38 [PMID:38481807] | ["Kim S", "Lee J", "Jung J", "Kim G", "Y | International journal of biolo | 2024 | 0 |
| The necroptosis cell death pathway drives neurodegeneration in Alzheimer's disea [PMID:38852117] | Balusu S, De Strooper B | Acta neuropathologica | 2024 | 0 |
| Hepatocyte-derived MASP1-enriched small extracellular vesicles activate HSCs to [PMID:35849032] | Liu X, Tan S, Liu H, Jiang J, Wang X, Li | Hepatology (Baltimore, Md.) | 2023 | 0 |
| Autophagy and exosomes coordinately mediate quercetin's protective effects on al [PMID:36965782] | ["Chen H", "Liu J", "Peng S", "Yang G", | The Journal of nutritional bio | 2023 | 0 |
| Extracellular vesicle-packaged ILK from mesothelial cells promotes fibroblast ac [PMID:37357686] | Huang Q, Sun Y, Peng L, Sun J, Sha Z, Li | Journal of extracellular vesic | 2023 | 0 |
| Deletion in chromosome 6 spanning alpha-synuclein and multimerin1 loci in the Ra [PMID:35701443] | ["Pattanayak R", "Underwood R", "Crowley | Scientific reports | 2022 | 0 |
| Capturing membrane trafficking events during 3D angiogenic development in vitro. [PMID:34415654] | ["Francis C", "Kushner E"] | Microcirculation (New York, N. | 2022 | 0 |
| In vivo Roles of Rab27 and Its Effectors in Exocytosis. [PMID:34483204] | ["Izumi T"] | Cell structure and function | 2021 | 0 |
| Insulin Resistance and Diabetes Mellitus in Alzheimer's Disease. [PMID:34069890] | Burillo J, Marqués P, Jiménez B, Gonzále | Cells | 2021 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning LIVER in their description or question text
Score: 0.633 · neuroinflammation · 2026-04-21
## Mechanistic Overview Liver-Derived Inflammatory Suppressors Downregulate Microglial IBA1 starts from the claim that m
Score: 0.622 · Alzheimer's disease · 2026-04-07
## Mechanistic Overview Optogenetic viral vector delivery via tFUS-mediated blood-brain barrier opening to restore hippo
Score: 0.621 · neurodegeneration · 2026-04-02
## Mechanistic Overview Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery starts from th
Score: 0.620 · pharmacology · 2026-04-21
## Mechanistic Overview CX3CR1-Targeted HDAC3 Knockdown in Microglia via AAV9 Delivery starts from the claim that modula
Score: 0.536 · molecular neurobiology · 2026-04-17
## Mechanistic Overview Cerebrospinal Fluid p-tau217-Guided Astrocyte-Derived Extracellular Vesicle Delivery of lncRNA-0
Score: 0.489 · molecular biology · 2026-04-20
## Mechanistic Overview C1q-Mediated Delivery of miR-33 Antisense Oligonucleotides for Enhanced APOE4 Lipidation starts
Score: 0.482 · neurodegeneration · 2026-04-02
Genetically modified microglia overexpressing mitochondrial export machinery package healthy mitochondria into extracell
Score: 0.470 · drug delivery · 2026-04-22
## Mechanistic Overview Intranasal IGFBPL1 Delivery via Olfactory Pathway starts from the claim that modulating IGFBPL1
Score: 0.461 · molecular neurobiology · 2026-04-21
## Mechanistic Overview CSF Neurofilament Light Chain-Guided Astrocyte-Derived Extracellular Vesicle Delivery of lncRNA-
Score: 0.427 · molecular biology · 2026-04-21
## Mechanistic Overview C1q-Targeted miR-33 ASO Delivery for APOE4 Hyper-Lipidation via Microglial Receptor-Mediated Tra
Score: 0.423 · molecular biology · 2026-04-21
## Mechanistic Overview C1q-Conjugated miR-33 ASO Brain Delivery for Enhanced APOE4 Lipidation starts from the claim tha
Score: 0.380 · metabolomics · 2026-04-25
Apolipoprotein E4-Mediated Metabolic Dysfunction Correction via Liver X Receptor Agonism